Emerging as a noteworthy development in the fight against obesity, Retatrutide is capturing considerable attention . This treatment combines the action of two established GLP-1 receptor agonists, semaglutide , plus an additional glucose-dependent incretin component. Initial study results have shown substantial body decrease in patients with excessi